• Skip to main content
  • Skip to primary sidebar

Tracking Health and Wellness Applications of Brain Science

Spanish
sb-logo-with-brain
  • Resources
    • Monthly eNewsletter
    • Solving the Brain Fitness Puzzle
    • The SharpBrains Guide to Brain Fitness
    • How to evaluate brain training claims
    • Resources at a Glance
  • Brain Teasers
    • Top 25 Brain Teasers & Games for Teens and Adults
    • Brain Teasers for each Cognitive Ability
    • More Mind Teasers & Games for Adults of any Age
  • Virtual Summits
    • 2019 SharpBrains Virtual Summit
    • Speaker Roster
    • Brainnovations Pitch Contest
    • 2017 SharpBrains Virtual Summit
    • 2016 SharpBrains Virtual Summit
    • 2015 SharpBrains Virtual Summit
    • 2014 SharpBrains Virtual Summit
  • Report: Pervasive Neurotechnology
  • Report: Digital Brain Health
  • About
    • Mission & Team
    • Endorsements
    • Public Speaking
    • In the News
    • Contact Us

Veterans Affairs won’t cover Biogen’s new “Alzheimer’s drug” given concerns over safety and lack of evidence

August 16, 2021 by SharpBrains

VA Health Sys­tem Won’t Cov­er Biogen’s Alzheimer’s Drug (The Wall Street Journal):

The Depart­ment of Vet­er­ans Affairs won’t cov­er Bio­gen Inc.’s new Alzheimer’s drug, the lat­est rebuke of the con­tro­ver­sial treat­ment since it was approved ear­li­er this summer.

The VA decid­ed not add the drug, called Aduhelm, to its for­mu­la­ry list of avail­able med­i­cines because of the drug’s risk of caus­ing seri­ous side effects and a lack of evi­dence that it improves cog­ni­tive func­tion, an agency spokes­woman said.

The VA pro­vides med­ical ben­e­fits to more than nine mil­lion vet­er­ans, and is the largest inte­grat­ed health­care sys­tem in the U.S. The agency is known for being a shrewd cus­tomer of pre­scrip­tion drugs, using its large pur­chas­ing pow­er to hag­gle steep dis­counts from man­u­fac­tur­ers. By law, the VA has greater lee­way than oth­er gov­ern­ment health pro­grams such as Medicare and Med­ic­aid to deny cov­er­age of med­i­cines it deems to be of poor val­ue … On Thurs­day, the VA post­ed on its web­site a doc­u­ment detail­ing its review of Aduhelm and its deci­sion. The doc­u­ment pro­vides guid­ance to doc­tors not to offer the drug to VA patients, but allows for doc­tors to seek excep­tions for cer­tain patients.

The Review:

VA’s Review of Aduhelm’s Clin­i­cal Evi­dence and Safe­ty (opens PDF). VA’s Pro­ject­ed Place in Therapy:

  • AD is a pro­gres­sive neu­ro­log­ic dis­or­der affect­ing approx­i­mate­ly 6 mil­lion Amer­i­cans. More women than men are affect­ed, and African Amer­i­cans and His­pan­ics are at high­er risk of devel­op­ing AD. Safe and effec­tive agents that halt or delay the pro­gres­sion of AD are clear­ly need­ed. Adu­canum­ab-avwa is a human mon­o­clon­al anti­body that pro­motes clear­ance of betaamy­loid plaques from the brain and is indi­cat­ed for the treat­ment of AD, specif­i­cal­ly, in patients with mild cog­ni­tive impair­ment or mild demen­tia stage of disease.
  • While VA PBM acknowl­edges the recent FDA deci­sion on adu­canum­ab-avwa, giv­en the lack of evi­dence of a robust and mean­ing­ful clin­i­cal ben­e­fit and the known safe­ty sig­nal, we rec­om­mend against offer­ing this agent to patients with Alzheimer’s demen­tia (mild or oth­er­wise) or mild cog­ni­tive impair­ment. How­ev­er, rec­og­niz­ing that there is an accel­er­at­ed FDA approval, we also rec­om­mend that if it is to be used by excep­tion then it should be uti­lized only in high­ly select­ed patients by experts and cen­ters that have the nec­es­sary diag­nos­tic and man­age­ment exper­tise— and only by those with the need­ed resources for close mon­i­tor­ing to assure safe­ty. As such, any use should be gov­erned by strin­gent reg­u­la­tion, and safe­ty and appro­pri­ate­ness of use mon­i­tored real time by VAMedSAFE.

News in Context:

  • Alzheimer’s & Demen­tia researchers chal­lenge FDA’s approval of Aduhelm giv­en lack of evi­dence for beta-amy­loid as a marker
  • Can the con­tro­ver­sial FDA approval of Aduhelm back­fire and delay the dis­cov­ery of actu­al Alzheimer’s treat­ments? (Yes, it can)
  • Study chal­lenges the “seduc­tive” amy­loid hypoth­e­sis of Alzheimer’s dis­ease (AD)
  • Cog­ni­tive train­ing, diet, exer­cise, and vas­cu­lar man­age­ment seen to improve cog­ni­tion even in peo­ple with genet­ic pre­dis­po­si­tion for demen­tia (APOE e4)

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health Tagged With: aducanumab, Aduhelm, Alzheimer's drug, Alzheimers-disease, betaamyloid plaques, Biogen, cognitive-function, FDA, Formulary, Healthcare-System, improves cognitive function, mild dementia, mild-cognitive-impairment, neurologic disorder, Veterans Affairs

Primary Sidebar

Top Articles on Brain Health and Neuroplasticity

  1. Can you grow your hippocampus? Yes. Here’s how, and why it matters
  2. How learning changes your brain
  3. To harness neuroplasticity, start with enthusiasm
  4. Three ways to protect your mental health during –and after– COVID-19
  5. Why you turn down the radio when you're lost
  6. Solving the Brain Fitness Puzzle Is the Key to Self-Empowered Aging
  7. Ten neu­rotech­nolo­gies about to trans­form brain enhance­ment & health
  8. Five reasons the future of brain enhancement is digital, pervasive and (hopefully) bright
  9. What Educators and Parents Should Know About Neuroplasticity and Dance
  10. The Ten Habits of Highly Effective Brains
  11. Six tips to build resilience and prevent brain-damaging stress
  12. Can brain training work? Yes, if it meets these 5 conditions
  13. What are cognitive abilities and how to boost them?
  14. Eight Tips To Remember What You Read
  15. Twenty Must-Know Facts to Harness Neuroplasticity and Improve Brain Health

Top 10 Brain Teasers and Illusions

  1. You think you know the colors? Try the Stroop Test
  2. Check out this brief attention experiment
  3. Test your stress level
  4. Guess: Are there more brain connections or leaves in the Amazon?
  5. Quick brain teasers to flex two key men­tal mus­cles
  6. Count the Fs in this sentence
  7. Can you iden­tify Apple’s logo?
  8. Ten classic optical illu­sions to trick your mind
  9. What do you see?
  10. Fun Mental Rotation challenge
  • Check our Top 25 Brain Teasers, Games and Illusions

Join 12,620 readers exploring, at no cost, the latest in neuroplasticity and brain health.

By subscribing you agree to receive our free, monthly eNewsletter. We don't rent or sell emails collected, and you may unsubscribe at any time.

IMPORTANT: Please check your inbox or spam folder in a couple minutes and confirm your subscription.

Get In Touch!

Contact Us

660 4th Street, Suite 205,
San Francisco, CA 94107 USA

About Us

SharpBrains is an independent market research firm tracking health and performance applications of brain science. We prepare general and tailored market reports, publish consumer guides, produce an annual global and virtual conference, and provide strategic advisory services.

© 2022 SharpBrains. All Rights Reserved - Privacy Policy